A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Opens in a new tab or window Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to the foveal center, according to a study that ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

The company offers year-round educational services on the conditions, using this month in particular to guide patients to ...

Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743–750. 4 Lundeen EA, Saydah S, Ehrlich J, Saaddine J. Self-reported vision impairment and ...

IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published. Zentrum für Augenheilkunde, Cologne Image Reading Center ...